The European Commission (EC) has granted conditional marketing authorization for Pfizer's Bosulif (bosutinib) anti-cancer drug in the European Union (EU). Bosulif is authorized in Europe for the treatment of adult patients with chronic ...
Tags: Pfizer Bosulif, cancer drug, drug
US Food and Drug Administration (FDA) has approved Pfizer's Bosulf (bosutinib) to treat adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) (CML) with resistance to prior therapy. Bosulif is a ...
Tags: bosulf, bosutinib, kinase inhibitor, Philadelphia chromosome-positive